Form 4: ALX Oncology CEO Sells Shares for Tax Obligations

ALX Oncology Holdings Inc. CEO Jason Lettmann sold 12,311 shares of common stock to cover tax obligations from vested restricted stock units.

Summary

• Jason Lettmann, Chief Executive Officer and Director of ALX Oncology Holdings Inc. (ALXO), reported the sale of 12,311 shares of common stock.
• The transaction occurred on March 19, 2026, at a price of $2.17 per share.
• The sale was executed to satisfy tax obligations associated with the vesting of performance-based restricted stock units.
• Following this transaction, Mr. Lettmann beneficially owns 293,609 shares of ALXO common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is a standard procedure for covering tax liabilities upon the vesting of equity awards, rather than a discretionary sale based on market outlook.

Positives

• The sale was explicitly for tax obligations related to the vesting of performance-based restricted stock units, indicating successful achievement of performance metrics and vesting of equity compensation.

Negatives

• A sale of shares by a Chief Executive Officer, even for tax purposes, results in a reduction of their direct ownership stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, which is solely for reporting an insider transaction.

Management Comments

• The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of performance-based restricted stock units.

Industry Context

StockSavvy.ai notes that insider sales for tax obligations are a common and routine occurrence when equity compensation vests, and typically do not indicate a change in management's fundamental outlook on the company's future prospects.

Comparison to Industry Standards

• This Form 4 filing is a standard disclosure for an insider transaction, specifically a sale to cover tax liabilities, which is a common practice across industries for executives receiving equity compensation.

Related Party Transactions

• Jason Lettmann, CEO and Director, sold 12,311 shares of ALX Oncology common stock to satisfy tax obligations related to vested performance-based restricted stock units.

Stakeholder Impact

• Shareholders: The sale by the CEO reduces his direct ownership stake, but the stated reason (tax obligations from vested equity) suggests it is a routine event rather than a signal of diminished confidence in the company's future performance.

Key Dates

Recommendation

The filing details a routine insider sale to cover tax obligations from vested equity. This type of transaction is common and does not typically signal a change in the company's fundamental outlook or the insider's long-term confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

ALX Oncology, ALXO, Jason Lettmann, Insider Trading, Form 4, Stock Sale, CEO, Restricted Stock Units, Tax Obligations